What's Going on with Vera Therapeutics Stock on Monday?

What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA) - Benzinga Benzinga España Italia 대한민국 日本 Français My Account Benzinga Edge Benzinga Research Benzinga Pro Login SPY 750.14 0.72% QQQ 723.71 1.56% BTC/USD 62304.98 2.0184% DIA 527.86 - GLD 380.24 0.56% TLT 85.28 0.26% Get Benzinga Pro Data & APIs Events Premarket Advertise Contribute España Italia 대한민국 日本 Français Login Register Benzinga Premium Services Financial News Financial News Large Cap Stocks Small-Cap Stocks Insider Trades Earnings Technology AI News Personal Finance ETF News Crypto News Dividend News Latest Rumors Latest Offerings News Investment Ideas Investment Ideas Stock of the Day Stock Whisper Index Analyst Ratings Analyst Color Financial Advisors Government Trades Trading Ideas Stock Screener Markets Markets Premarket Movers After Hours Options ETFs Commodities Prediction Markets Private Markets Bonds Futures Forex Top Stocks Top Stocks Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Nvidia (NVDA) Alphabet (GOOGL) Meta Platforms (META) Microsoft (MSFT) StreetTracks Gold Shares (GLD) IBIT Bitcoin Trust (IBIT) Top Value Stocks Top Momentum Stocks Top Growth Stocks Top Quality Stocks Learn Learn Investing Guides Personal Finance Mortgages Best Credit Cards Best Dividend Stocks Best Swing Trade Stocks Investment Ideas Investment Ideas Stock of the Day Stock Whisper Index Analyst Ratings Analyst Color Financial Advisors Government Trades Trading Ideas Stock Screener Markets Markets Premarket Movers After Hours Options ETFs Commodities Prediction Markets Private Markets Bonds Futures Forex Top Stocks Top Stocks Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Nvidia (NVDA) Alphabet (GOOGL) Meta Platforms (META) Microsoft (MSFT) StreetTracks Gold Shares (GLD) IBIT Bitcoin Trust (IBIT) Top Value Stocks Top Momentum Stocks Top Growth Stocks Top Quality Stocks Learn Learn Investing Guides Personal Finance Mortgages Best Credit Cards Best Dividend Stocks Best Swing Trade Stocks Research My Stocks Tools Free Benzinga Pro Trial Calendars Analyst Ratings Calendar Conference Call Calendar Dividend Calendar Earnings Calendar Economic Calendar Events Calendar FDA Calendar Guidance Calendar IPO Calendar M&A Calendar Unusual Options Activity Calendar SPAC Calendar Stock Split Calendar Trade Ideas Stock Reports Insider Trades Trade Idea Feed Analyst Ratings Unusual Options Activity Heatmaps Free Newsletter Government Trades Perfect Stock Portfolio Easy Income Portfolio Short Interest Most Shorted Largest Increase Largest Decrease Calculators Options Profit Calculator Margin Calculator Forex Profit Calculator 100x Options Profit Calculator Covered Call Calculator Cash-Secured Put Calculator Long Call Calculator Long Put Calculator Screeners Stock Screener Top Momentum Stocks Top Quality Stocks Top Value Stocks Top Growth Stocks Compare Best Stocks Best Momentum Stocks Best Quality Stocks Best Value Stocks Best Growth Stocks Recent Markets SPY 750.14 0.72% QQQ 723.71 1.56% BTC/USD 62304.98 2.0184% DIA 527.86 - GLD 380.24 0.56% TLT 85.28 0.26% July 6, 2026 11:39 AM 2 min read What's Going on with Vera Therapeutics Stock on Monday? • Vera Therapeutics stock is building positive momentum. Why is VERA stock advancing? Vera Therapeutics Awaits Key FDA Decision Over the past month, the stock has gained around 30%. With the action date on July 7, the company seeks accelerated approval of atacicept in patients with IgA Nephropathy (IgAN), an autoimmune kidney disease that occurs when immunoglobulin A (IgA) antibodies build up in the kidneys. The buildup causes inflammation that damages the glomeruli (tiny filters in the kidneys), making it harder to filter waste from the blood. If approved, atacicept could offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection. ORIGIN 3 Trial Data Supports The BLA submission for atacicept is supported by data from a prespecified interim analysis of the ORIGIN 3 trial. The trial met the primary endpoint of reduction in proteinuria at week 36 . Atacicept-treated patients achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo at week 36 . In June, Vera Therapeutics aligned with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan to support full approval for atacicept in adults with IgAN . The eGFR results are now expected in the third quarter of 2026, pulled forward from 2027. Pending these results, Vera Therapeutics plans to submit an sBLA for full approval in the fourth quarter of 2026. Novartis Remains Key Competitor In February, Novartis shared final results from the Phase 3 ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia . After the trial data, Novartis plans to submit for traditional approval in 2026. VERA S